Journal
JOURNAL OF LIPOSOME RESEARCH
Volume 17, Issue 1, Pages 1-14Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/08982100601186474
Keywords
tumor targeting; antinuclear antibody; liposomes; lipid-core micelles; gamma-imaging; doxorubicin; photodynamic therapy
Funding
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055519] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB001961] Funding Source: NIH RePORTER
- NHLBI NIH HHS [2R01 HL55519] Funding Source: Medline
- NIBIB NIH HHS [R01 EB001961] Funding Source: Medline
- PHS HHS [R01 EN002995] Funding Source: Medline
Ask authors/readers for more resources
Liposomes and lipid-core micelles prepared of polyethylene glycol-phosphatidylethanolamine (PEG-PE) conjugates have been modified with nucleosome-specific monoclonal antinuclear autoantibody (ANA) 2C5 (mAb 2C5) specifically recognizing a broad variety of cancer cells through the cancer cell surface-bound nucleosomes. mAb 2C5 preserves its specific properties upon the binding with the lipid-based pharmaceutical nanocarriers, and 2C5-modified immunoliposomes and immunomicelles demonstrate an enhanced binding with tumor cells both in vitro and in vivo. We have investigated the delivery of therapeutic and diagnostic agents with such tumor-targeted immunoliposomes and immunomicelles to various tumors in vivo and in vitro. Both lipid-based nanocarriers provided enhanced tumor delivery of imaging agents (In-111) and antitumor drugs (doxorubicin and photodynamic therapy agents) to tumor cells under different experimental settings. Pharmaceutical lipid-based nanoparticular carriers modified with mAb 2C5 could represent universal systems for tumor-specific delivery of various soluble and insoluble pharmaceuticals.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available